

La Renon



Unleashing a  
new era in  
**ACID  
SUPPRESSION**

**VONOGRESS**

Vonoprazan 10 mg and 20 mg Tablets


# VONOGRESS

## Vonoprazan 10 mg and 20 mg Tablets

### BACKGROUND:

- Over the time, GERD has become common globally. Despite PPI treatment, many patients remain dissatisfied. Notably, *H. pylori* infection inversely correlates with GERD. Global prevalence of GERD is 20% and *H. pylori* is 50%.<sup>1,2,3</sup>
- Vonoprazan (VPZ), a novel potassium-competitive acid blocker (P-CAB), provides stronger, faster, and longer acid suppression than PPIs, showing superior efficacy against GERD, *H. pylori*, and ulcers, addressing therapy limitations.<sup>1</sup>

### MECHANISM OF ACTION OF PPIs AS COMPARED WITH P-CABS<sup>4</sup>:



- PPIs convert to their active form in acid milieu within the secretory canaliculi and bind covalently to H<sup>+</sup>/K<sup>+</sup>-ATPases in a stimulated parietal cell.

- P-CABs accumulate in high concentrations in secretory canaliculi and bind reversibly to H<sup>+</sup>/K<sup>+</sup>-ATPases **without requiring an acidic environment for activation.**

### VONOPRAZAN FULL & FAST EFFECT FROM FIRST DOSE<sup>5</sup>:




Fig. Time course of acid inhibition by P-CABs and PPIs.

# CLINICAL EVIDENCES:

## 1. EFFICACY OF VONOPRAZAN FOR PROTON PUMP INHIBITOR-RESISTANT REFLUX ESOPHAGITIS (RE)<sup>6</sup>:

**Total Patients:** 24 PPI-resistant RE patients

**Duration:** 4 Weeks

**Dose:** Vonoprazan 20 mg

**Result:**




Fig. Endoscopic healing rate of vonoprazan therapy at 20 mg for 4 weeks for proton pump inhibitor-resistant reflux esophagitis. LA: Los Angeles.

**Conclusion:** Vonoprazan effectively treats most PPI-resistant RE patients. Among these patients, a 4-week, 20 mg VPZ course resulted in a 90% endoscopic healing rate.

## 2. COMPARISON OF FIRST-LINE H. PYLORI ERADICATION THERAPIES<sup>7</sup>:

VPZ-Based Regimen		PPI-Based Regimen	
Regimen	Eradication Rate	Regimen	Eradication Rate
VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	95.8%	LPZ: 30 mg bid or RPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	69.6%
VPZ: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	90.9%	RPZ: 10 mg bid or ESO: 20 mg bid AMX: 750 mg bid CLR: 200 or 400 mg bid	72.8%

\*AMX: Amoxicillin, CLR: Clarithromycin, ESO: Esomeprazole, LPZ: Lansoprazole, RPZ: Rabeprazole, VPZ: Vonoprazan.

# VONOGRESS

## Vonoprazan 10 mg and 20 mg Tablets

### DESCRIPTION:

Vonogress-10/20 tablets contain Vonoprazan, a potent inhibitor of gastric acid secretion, available in 10 mg and 20 mg strengths. Vonoprazan (VPZ) offers superior symptomatic relief through its innovative mechanism and sustained therapeutic effectiveness.

### INDICATIONS:

- Treatment of reflux esophagitis (RE), gastric ulcer (GU) & duodenal ulcer (DU).
- Prevention of recurrence of gastric ulcer or duodenal ulcer during low-dose aspirin / NSAIDs administration.
- In Helicobacter pylori treatment in combination with both amoxicillin and clarithromycin or with amoxicillin alone.

### MECHANISM OF ACTION:

Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H<sup>+</sup> /K<sup>+</sup>-ATPase enzyme system in a potassium-competitive manner.

VONOGRESS

It suppresses basal and stimulated gastric acid secretion at the secretory surface of gastric parietal cells.

### KEY FEATURES:

- **Faster Onset:** A faster onset of action than PPIs.<sup>8</sup>
- **Non-Acid Activation:** Doesn't require stomach acid for effectiveness.<sup>8</sup>
- **Meal Independent:** Vonoprazan effect is not influenced by meals.<sup>4</sup>
- **Stronger Suppression:** Provides potent and sustained inhibition of gastric acid secretion.<sup>1</sup>
- **Long Lasting Effect:** Stable and persists in the stomach, exerting a long-lasting effect.<sup>8</sup>
- **Potassium Competitive:** Competes with potassium for proton pump binding, boosting efficacy.<sup>8</sup>
- **Higher Efficacy:** Superior effectiveness in treating conditions like GERD and H. pylori infection compared to PPIs.<sup>1,9</sup>
- **Reduced Resistance:** Suitable alternative for patients with PPI resistance or intolerance.<sup>10</sup>

**DOSAGE:** The recommended dose of vonoprazan is 10 mg -20 mg OD or as suggested by the healthcare professional.

**PRESENTATION:** Vonogress-10/20 available as a strip of 10 tablets

#### References:

1. Kang et al. Medicine (2018) 97:39.
2. Ann Esophagus 2022;5:7
3. World J Gastroenterol 2014 February 14; 20(8): 1503-1509
4. Gastroenterology Rev 2023; 18 (8): 47-55
5. Gastroenterology. 2018 Dec;16:570-90.
6. Digestion 2017;95:156-161
7. Pharmaceuticals 2020, 13, 276
8. Japanese Society of Gastroenterology 2020, 31 August 2020
9. Murakami K, et al. Gut 2016;65:1439-1446.
10. BIOMEDICAL REPORTS 14: 32, 2021



Scan for more  
Prescribing  
Information.

#### La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,

S.G. Highway, Ahmedabad-380015, Gujarat, India.

Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998

E-mail: info@larenon.com | Web: www.larenon.com

👤 I am: \_\_\_\_\_

📞 Call me on: \_\_\_\_\_

✉ Mail me at: \_\_\_\_\_

©2024 All rights reserved, La Renon Healthcare Private Limited